Acyclovir Sodium

Chickenpox, Encephalitis, Herpes Simplex, Neutropenia + 18 more

Treatment

20 Active Studies for Acyclovir Sodium

What is Acyclovir Sodium

Acyclovir

The Generic name of this drug

Treatment Summary

Acyclovir is a medication used to treat various types of viral infections, such as herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. It is the preferred treatment for these viruses and can be given to children as young as six years old. Acyclovir was approved by the FDA in 1982.

Zovirax

is the brand name

image of different drug pills on a surface

Acyclovir Sodium Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zovirax

Acyclovir

1982

496

Effectiveness

How Acyclovir Sodium Affects Patients

Acyclovir helps to stop the spread of certain types of viruses by blocking their replication. It is generally considered to be a safe drug, as overdose is rare in healthy people.

How Acyclovir Sodium works in the body

Acyclovir works by interfering with viral DNA. It is changed into a form that is more easily used by the virus. This form then binds to the virus's DNA polymerase and blocks it from functioning properly. The blocked enzymes prevent the virus from making copies of itself, which stops the infection from spreading.

When to interrupt dosage

The quantity of Acyclovir Sodium is contingent upon the specified condition, for instance Cytomegalovirus Infections, serious Genital herpes and Herpes simplex type I reactivation. The amount of dosage can be identified in the table below, in accordance with the method of administration (e.g. Cream - Topical or Injection, powder, lyophilized, for solution - Intravenous).

Condition

Dosage

Administration

Bone Marrow Transplant

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Neutropenia

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Simplex Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Chickenpox

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Communicable Diseases

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Immunocompromised

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Genitalis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Shingles

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Keratitis, Herpetic

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Cytomegalovirus Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

prophylaxis of VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Bell Palsy

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Encephalitis, Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

prophylaxis of HSV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Warnings

Acyclovir Sodium Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Acyclovir may interact with Pulse Frequency

There are 20 known major drug interactions with Acyclovir Sodium.

Common Acyclovir Sodium Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Acyclovir.

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Neomycin.

Procainamide

Major

The excretion of Procainamide can be decreased when combined with Acyclovir.

Tenofovir

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir alafenamide.

Acyclovir Sodium Toxicity & Overdose Risk

An overdose of Cytoxan may cause agitation, confusion, seizures, fatigue, and kidney deposits. These effects are more likely to occur when the drug is taken without monitoring of electrolyte and fluid levels or when kidney function is low. Treatment for an overdose includes providing supportive care and addressing any symptoms that arise.

image of a doctor in a lab doing drug, clinical research

Acyclovir Sodium Novel Uses: Which Conditions Have a Clinical Trial Featuring Acyclovir Sodium?

34 active investigations are examining the utility of Acyclovir Sodium in prophylactically thwarting VZV reactivation, Immunocompromised states and Communicable Diseases.

Condition

Clinical Trials

Trial Phases

Encephalitis, Herpes Simplex

0 Actively Recruiting

Herpes Simplex Infections

0 Actively Recruiting

Herpes Genitalis

0 Actively Recruiting

VZV re-activation

0 Actively Recruiting

Chickenpox

3 Actively Recruiting

Phase 3

Neutropenia

4 Actively Recruiting

Phase 1, Phase 2, Phase 3

Cytomegalovirus Infections

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Bone Marrow Transplant

27 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Keratitis, Herpetic

0 Actively Recruiting

prophylaxis of HSV re-activation

0 Actively Recruiting

Shingles

3 Actively Recruiting

Phase 2, Phase 1

Herpes Simplex

0 Actively Recruiting

Herpes Labialis

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

prophylaxis of VZV re-activation

0 Actively Recruiting

Bell Palsy

0 Actively Recruiting

Herpes Labialis

0 Actively Recruiting

Acyclovir Sodium Reviews: What are patients saying about Acyclovir Sodium?

5

Patient Review

6/5/2014

Acyclovir Sodium for Inflammation of the Brain caused by Herpes Simplex Virus

I was given this medication in the ER for a severe headache and numbness on my right side. However, it caused a lot of other problems, some of which were worse than what I came in with. The most serious one that I found out about the day after they admitted me was kidney failure. My kidney function was down to 28%. They say it should come back, but now I'm stuck in the hospital until my numbers go down. DO NOT USE THIS DRUG! Two other people had the same complications that night in the ER and they stopped using it.

5

Patient Review

8/26/2017

Acyclovir Sodium for Herpes Infection of Brain and Surrounding Tissue

I went to the ER and was diagnosed with herpes zoster of cerebrospinal fluid. I was immediately put on this medication and it completely cleared up within three days.

5

Patient Review

2/6/2016

Acyclovir Sodium for Prevent Recurrent Herpes Simplex Infection

This drug completely saved my life when I was admitted to the hospital with a systemic HSV-1 infection. I had meningitis and encephalitis caused by HSV-1, but after using this treatment, I dramatically improved.

3.7

Patient Review

1/18/2009

Acyclovir Sodium for Shingles

I was treated with this medication for viral meningitis. I had to stay in the hospital for ten days, and then had three more at-home with a health professional. Unfortunately, I experienced bad hallucinations and gross hematuria (blood in urine) that led to me being readmitted for another week. Even now, my urine shows microscopic amounts of blood. I was told by three different doctors that this was a side effect of the medication.

2

Patient Review

4/28/2008

Acyclovir Sodium for Herpes Simplex Infection

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about acyclovir sodium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is acyclovir sodium used for?

"This medication can help treat outbreaks of herpes simplex infection on the skin, in mucous membrane areas, or in the brain. It can also help treat shingles infection."

Answered by AI

What should you not do while taking acyclovir?

"What should you avoid while taking acyclovir?

Do not take this medicine with any of the following medications:

valacyclovir.

This medicine may also interact with the following medications:

bosutinib.

chloramphenicol.

dicumarol.

female hormones, like estrogens or progestins and birth control pills, patches, rings, implants, or injections.

What are the bad side effects of acyclovir?

Common (1% to 10%): malaise, conjunctivitis, photosensitivity reaction, vertigo, tremor, headache. Rare (0.01% to 0.1%): seizure, status epilepticus. Frequency not reported: acute angle-closure glaucoma, auditory hallucinations, abnormal electroencephalogram (EEG), neuropathy, neuropsychiatric symptoms/reactions8 мая 2020 г.

What types of drugs are antiviral?

What Antiviral Medications Treat Influenza?

amantadine (Symmetrel)

rimantadine (Flumadine"

Answered by AI

Can you take acyclovir everyday?

"This medication is typically taken 2-5 times per day for 5-10 days, starting as soon as possible after symptoms start. When taken to prevent genital herpes outbreaks, it is usually taken 2-5 times per day for up to 12 months."

Answered by AI

Clinical Trials for Acyclovir Sodium

Image of Princess Margaret Cancer Centre, University Health Network in Toronto, Canada.

Psychoeducation for Caregivers of Bone Marrow Transplant Patients

18+
All Sexes
Toronto, Canada

Background: Caregivers of patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for hematological malignancies face significant challenges that can impact their well-being. This study aims to evaluate the feasibility and acceptability of an adapted psychoeducational intervention(PEI) designed to support these caregivers. Methods: This study will recruit caregivers of alloHCT patients. Participants will be enrolled during pre-transplant clinic visits, typically 2-4 weeks before the scheduled transplant. The intervention consists of eight sessions over 12 weeks, delivered via Microsoft Teams by a nurse facilitator. In the adapted PEI, participants will learn stress management, coping strategies, energy management, goal-setting, communication skills, and support resource access through interactive exercises. Data Collection: Participants will complete questionnaires at three time points: pre-intervention, one month post-transplant, and three months post-transplant. The final assessment will include additional questions about feasibility, acceptability and the initial efficacy of the adapted PEI. Outcomes: The primary outcomes will be the feasibility and acceptability of the adapted psychoeducational intervention (PEI). Secondary outcomes will include initial efficacy of the adapted PEI on caregiver outcomes such as depression, anxiety, satisfaction with caregiving and quality of life. Significance: This research aims to assess the feasibility, acceptability and initial efficacy of implementing the adapted PEI for alloHCT caregivers. If found feasible and acceptable, this intervention could potentially improve caregivers' ability to manage caregiving stressors and pave the way for larger-scale randomized studies and implementation.

Recruiting
Has No Placebo

Princess Margaret Cancer Centre, University Health Network

Samantha Mayo, RN, PhD

Image of Georgetown University School of Medicine in Washington, United States.

Mosaic Website for Blood Cancer Patients

18+
All Sexes
Washington, United States

The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups). The main questions this trial aims to answer are: 1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.

Recruiting
Has No Placebo

Georgetown University School of Medicine (+3 Sites)

Image of University of Kansas Cancer Center in Kansas City, United States.

High Intensity Interval Training for Bone Marrow Transplant

18 - 80
All Sexes
Kansas City, KS

The goal of this clinical trial is to learn how a remotely monitored high-intensity interval training (REMM-HIIT) affects the cardiorespiratory fitness and physical function for patients planning to undergo stem cell transplantation. The main questions it aims to answer are: Is there a change in the participant's cardiorespiratory fitness level? Is there a change in the participant's physical function? Researchers will compare the REMM-HIIT program to a control group of participants who do not take part in the training program to see if REMM-HIIT helps improve stem cell transplantation outcomes. Participants will: * Complete cardiopulmonary exercise testing (CPET) 4 times during the study * Do basic tests to measure physical function 6 times during the study * Answer questions about their life and how they are feeling 6 times during the study * Wear a device to keep track of step counts and heart rate daily * Keep a log of every time they exercise throughout the study * Optionally, provide blood and stool samples 6 times during the study

Waitlist Available
Has No Placebo

University of Kansas Cancer Center (+2 Sites)

Anthony Sung, MD

Have you considered Acyclovir Sodium clinical trials?

We made a collection of clinical trials featuring Acyclovir Sodium, we think they might fit your search criteria.
Go to Trials
Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY

The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.

Phase 2
Recruiting

Weill Cornell Medical College

Pinkal Desai, MD

Bristol-Myers Squibb

Have you considered Acyclovir Sodium clinical trials?

We made a collection of clinical trials featuring Acyclovir Sodium, we think they might fit your search criteria.
Go to Trials
Image of Dana-Farber Cancer Institute in Boston, United States.

Digital Support for Bone Marrow Transplant

18+
All Sexes
Boston, MA

The overall goal of this study is to assess the efficacy of the care.coach Avatar™ in improving anxiety and quality of life for patients undergoing outpatient transplant. After care.coach Avatar™ content and scheduling ("digital intervention" or "program") has been optimized for outpatient allogeneic hematopoietic stem cell transplantation (HCT), a randomized controlled trial (RCT) will be conducted of the digital versus usual supportive care program for outpatient HCT recipients. Potential improvements in anxiety and quality of life will be evaluated, with the intent of increasing comfortability with outpatient transplant and expanding the population of eligible patients willing to receive their transplants in an outpatient setting.

Recruiting
Has No Placebo

Dana-Farber Cancer Institute

Victor Wang, MS

Friendi.fi Corporation

Have you considered Acyclovir Sodium clinical trials?

We made a collection of clinical trials featuring Acyclovir Sodium, we think they might fit your search criteria.
Go to Trials